ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$9.79 USD
-0.14 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.98 +0.19 (1.94%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRY 9.79 -0.14(-1.41%)
Will SPRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for SPRY
Is SPRY gaining bearish strength? 1,2,3 Retracement Bearish shows up after slipping 1.41%
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) Gains on Japanese Approval for Neffy Nasal Spray
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
SPRY Gains Approval in Japan for Needle-Free Allergy Treatment